SPY072

Monoclonal antibody

Earlyevidence

Evidence outlook

Hidradenitis Suppurativa: mid-stage studies underway, no completed readout

In Hidradenitis Suppurativa, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.

Development in Psoriatic Arthritis stopped (2026-11-03) after a negative readout. Development continues in another indication. Source

Development in Rheumatoid Arthritis stopped (2026-11-03) as a strategic decision by the sponsor. Development continues in another indication. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Hidradenitis Suppurativa
Other / comorbidity
Phase 1 (1)
Other / comorbidity
NCT06622070 · Spyre Therapeutics, Inc.
2024-11-18 – 2026-07-28 · Healthy
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Hidradenitis Suppurativa: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SPY072: this drugPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FPartial signal
NCT04242498: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results).
NCT04242446: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Partial signal
NCT03713632: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): AIN457 Q2W 42.3 Percentage of Participants | AIN457 Q4W 46.1 Percentage of Participants | Placebo 31.2 Percentage of Participants
NCT03713619: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): Secukinumab 1 - Q2W 45 Percentage of participants | Secukinumab 2 - Q4W 41.8 Percentage of participants | Placebo 33.7 Percentage of participants
Afimkibart
Phase 3(overall)
Monoclonal antibodyTL1A
Partial signal(overall)
No reviewed efficacy summary in this indication
LutikizumabPhase 3Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
RemibrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Opzelura)Phase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2/3Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
Spesolimab (Spevigo)Phase 2/3Monoclonal antibodyIL-36 receptornot yet gradedNo reviewed efficacy summary in this indication
AbdakibartPhase 2Monoclonal antibodyIL-1 betanot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
EltrekibartPhase 2Monoclonal antibodyCXCR1/2not yet gradedNo reviewed efficacy summary in this indication
OlatorepatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ORKA-002Phase 2Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
SAR442970Phase 2——not yet gradedNo reviewed efficacy summary in this indication
SAR445399Phase 2Monoclonal antibodyIL-1R3 (IL1RAP)not yet gradedNo reviewed efficacy summary in this indication
SPY002
Phase 2(overall)
Monoclonal antibodyTL1A
not yet graded(overall)
No reviewed efficacy summary in this indication
SSGJ-627
Phase 2(overall)
Biologic (subtype unspecified)TL1A
not yet graded(overall)
No reviewed efficacy summary in this indication
TulisokibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
ZasocitinibPhase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
XmAb942
Phase 1/2(overall)
Monoclonal antibodyTL1A
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-1451
Phase 1(overall)
UndisclosedIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
SAR447971
Phase 1(overall)
Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
TL-003
Phase 1(overall)
Multispecific antibodyTL1A, IL-23 p19
not yet graded(overall)
No reviewed efficacy summary in this indication
TipasertidegDiscontinuedSmall moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SPY072 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 2Hidradenitis SuppurativaRecruiting
Est. primary completion 2027-10 · NCT07766005 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 November 2026Topline resultSKYWAY: SPY072 misses its primary endpoints in psoriatic arthritis and axial spondyloarthritis; no further development in rheumatic diseases
US · Spyre Therapeutics · Source ↗
25 August 2026Topline resultSKYWAY RA cohort: SPY072 low dose met the DAS28-CRP primary endpoint; not prioritised as RA monotherapy
US · Spyre Therapeutics · Source ↗